Streetbeat News

KNBWY

Kirin Holdings Co., Ltd.

https://www.kirin.co.jp/company/about/kirinbrewery/

Industry

Breweries

Open

13.90

Mkt cap

11B

Volume

5.7K

High

13.90

P/E Ratio

16.06

52-wk high

16.25

Low

13.81

Div yield

0.03

52-wk low

12.81

Kura Oncology announced a partnership with Kyowa Kirin to develop and commercialize the blood cancer therapy ziftomenib.

Portfolio Pulse from

November 20, 2024 | 11:15 pm

Kura Oncology and Kyowa Kirin have entered a global strategic collaboration to develop and commercialize ziftomenib for acute leukemias. Kura will receive $330 million upfront and up to $1.2 billion in milestone payments. The companies will share profits 50/50 in the U.S., with Kura leading U.S. development and sales, while Kyowa Kirin will have exclusive rights outside the U.S.

Portfolio Pulse from

November 20, 2024 | 10:15 pm

Kura Oncology and Kyowa Kirin have entered a global strategic collaboration to develop and commercialize Ziftomenib for acute leukemias. Kura will receive a $330 million upfront payment and up to $1.2 billion in milestone payments.

Portfolio Pulse from

November 20, 2024 | 10:15 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.